Virtu KCG Holdings’s Myriad Genetics MYGN Stock Holding History

Virtu KCG Holdings’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$291K	Sell	11,246 -35,678	-76%	-$757K	0.01%	1712
2017 Q1	$901K	Buy	+46,924	New	+$831K	0.03%	795
2016 Q3	–	Sell	-31,893	Closed	-$976K	–	3324
2016 Q2	$976K	Buy	+31,893	New	+$1.11M	0.02%	773
2016 Q1	–	Sell	-27,483	Closed	-$1.19M	–	3383
2015 Q4	$1.19M	Buy	+27,483	New	+$1.16M	0.02%	715
2015 Q1	–	Sell	-11,162	Closed	-$380K	–	3621
2014 Q4	$380K	Buy	+11,162	New	+$396K	0.01%	2039
2014 Q1	–	Sell	-29,851	Closed	-$626K	–	3875
2013 Q4	$626K	Sell	29,851 -10,239	-26%	-$259K	0.01%	1696
2013 Q3	$942K	Buy	+40,090	New	+$1.14M	0.01%	1228

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Virtu KCG Holdings's MYGN Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Myriad Genetics (MYGN) stake by 76% in Q2 2017, selling an estimated $757K and leaving 11,246 shares worth $291K. The position accounts for 0.01% of the portfolio, ranked #1712.

Virtu KCG Holdings first reported a position in MYGN in Q3 2013 and has held it in 7 quarters since. The position peaked at $1.19M in Q4 2015. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

Virtu KCG Holdings held 11,246 shares of Myriad Genetics worth $291K as of Q2 2017.
Virtu KCG Holdings sold 35,678 Myriad Genetics shares in Q2 2017, an estimated $757K.
Myriad Genetics made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1712 holding.
Virtu KCG Holdings first reported a position in Myriad Genetics in Q3 2013 and has held it in 7 quarters since.
Virtu KCG Holdings's Myriad Genetics position peaked at $1.19M in Q4 2015.
239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.